NASDAQ:TECH - Bio-Techne Stock Price, Price Target & More

$151.65 -1.70 (-1.11 %)
(As of 04/19/2018 03:00 PM ET)
Previous Close$153.35
Today's Range$151.39 - $154.55
52-Week Range$99.96 - $154.55
Volume39,460 shs
Average Volume177,470 shs
Market Capitalization$5.73 billion
P/E Ratio42.04
Dividend Yield0.84%
Beta0.7

About Bio-Techne (NASDAQ:TECH)

Bio-Techne logoBio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells biotechnology reagents, instruments, and clinical diagnostic controls worldwide. It operates through three segments: Biotechnology, Protein Platforms, and Diagnostics. The Biotechnology segment offers native and recombinant proteins, monoclonal and polyclonal antibodies, immunoassays, biologically active chemical compounds, and in situ genomic hybridization assays for the research and clinical diagnostics markets. It also provides various products, which serves as predictive biomarkers and therapeutic targets for various human diseases and conditions, including cancer, autoimmunity, diabetes, hypertension, obesity, inflammation, neurological disorders, and kidney failure. The Protein Platforms segment develops, manufactures, and sells tools, such as Biologics platform that enables researchers interrogate protein purity and identify contaminants during the development and production of biologics; Simple Western platform for protein analysis and identification; SimplePlex platform, an enzyme-linked immunosorbent assay for use in research and clinical diagnostics; and Single Cell Western platform to elucidate the properties of individual cells to understand cell behavior. The Diagnostics segment offers controls and calibrators for hematology clinical instruments; blood chemistry and blood gas quality controls, diagnostic immunoassays, and other bulk and custom reagents for the in vitro diagnostic market; bulk purified proteins, enzymes, disease-state plasmas, infectious disease antigens, and processed serums to the clinical diagnostic industry; and Paratest, a novel and convenient stool collection and test device for the veterinary market. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.

Receive TECH News and Ratings via Email

Sign-up to receive the latest news and ratings for TECH and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryLife Sciences Tools & Services
SectorMedical
SymbolNASDAQ:TECH
CUSIP87837710
Phone612-379-8854

Debt

Debt-to-Equity Ratio0.36%
Current Ratio3.10%
Quick Ratio2.49%

Price-To-Earnings

Trailing P/E Ratio42.04
Forward P/E Ratio37.82
P/E Growth2.55

Sales & Book Value

Annual Sales$563 million
Price / Sales10.09
Cash Flow$5.0016 per share
Price / Cash30.32
Book Value$25.44 per share
Price / Book5.96

Profitability

EPS (Most Recent Fiscal Year)$3.42
Net Income$76.08 million
Net Margins19.17%
Return on Equity14.39%
Return on Assets8.89%

Miscellaneous

Employees1,800
Outstanding Shares37,470,000

How to Become a New Pot Stock Millionaire

Bio-Techne (NASDAQ:TECH) Frequently Asked Questions

What is Bio-Techne's stock symbol?

Bio-Techne trades on the NASDAQ under the ticker symbol "TECH."

How often does Bio-Techne pay dividends? What is the dividend yield for Bio-Techne?

Bio-Techne announced a quarterly dividend on Wednesday, February 7th. Stockholders of record on Friday, February 16th will be given a dividend of $0.32 per share on Friday, March 2nd. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.84%. The ex-dividend date is Thursday, February 15th. View Bio-Techne's Dividend History.

How were Bio-Techne's earnings last quarter?

Bio-Techne (NASDAQ:TECH) issued its earnings results on Tuesday, February, 6th. The biotechnology company reported $1.02 EPS for the quarter, beating analysts' consensus estimates of $0.92 by $0.10. The biotechnology company had revenue of $154.15 million for the quarter, compared to analyst estimates of $145.93 million. Bio-Techne had a net margin of 19.17% and a return on equity of 14.39%. The business's quarterly revenue was up 16.9% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.81 earnings per share. View Bio-Techne's Earnings History.

When is Bio-Techne's next earnings date?

Bio-Techne is scheduled to release their next quarterly earnings announcement on Wednesday, May, 2nd 2018. View Earnings Estimates for Bio-Techne.

What price target have analysts set for TECH?

6 equities research analysts have issued 12-month target prices for Bio-Techne's shares. Their predictions range from $115.00 to $163.00. On average, they expect Bio-Techne's share price to reach $148.75 in the next twelve months. View Analyst Ratings for Bio-Techne.

Who are some of Bio-Techne's key competitors?

Who are Bio-Techne's key executives?

Bio-Techne's management team includes the folowing people:
  • Mr. Charles R. Kummeth, Pres, CEO & Director (Age 58)
  • Mr. James T. Hippel, Sr. VP of Fin., CFO & Principal Accounting Officer (Age 47)
  • Mr. N. David Eansor, Sr. VP of Biotechnology Division (Age 57)
  • Mr. Robert M. Gavin, Sr. VP of Protein Platforms Division (Age 50)
  • Mr. Kevin S. Gould, Sr. VP of Diagnostics Division (Age 52)

Has Bio-Techne been receiving favorable news coverage?

Media stories about TECH stock have trended somewhat negative recently, according to Accern. Accern identifies positive and negative media coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Bio-Techne earned a news sentiment score of -0.03 on Accern's scale. They also gave media stories about the biotechnology company an impact score of 47.01 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near term.

How do I buy shares of Bio-Techne?

Shares of TECH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Bio-Techne's stock price today?

One share of TECH stock can currently be purchased for approximately $151.65.

How big of a company is Bio-Techne?

Bio-Techne has a market capitalization of $5.73 billion and generates $563 million in revenue each year. The biotechnology company earns $76.08 million in net income (profit) each year or $3.42 on an earnings per share basis. Bio-Techne employs 1,800 workers across the globe.

How can I contact Bio-Techne?

Bio-Techne's mailing address is 614 MCKINLEY PLACE NE, MINNEAPOLIS MN, 55413. The biotechnology company can be reached via phone at 612-379-8854 or via email at [email protected]


MarketBeat Community Rating for Bio-Techne (TECH)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  170 (Vote Outperform)
Underperform Votes:  209 (Vote Underperform)
Total Votes:  379
MarketBeat's community ratings are surveys of what our community members think about Bio-Techne and other stocks. Vote "Outperform" if you believe TECH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TECH will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Bio-Techne (NASDAQ:TECH) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
6 Wall Street analysts have issued ratings and price targets for Bio-Techne in the last 12 months. Their average twelve-month price target is $148.75, suggesting that the stock has a possible downside of 1.91%. The high price target for TECH is $163.00 and the low price target for TECH is $115.00. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.832.712.672.60
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $148.75$148.75$138.00$126.3333
Price Target Upside: 1.91% downside5.24% upside1.44% downside3.69% upside

Bio-Techne (NASDAQ:TECH) Consensus Price Target History

Price Target History for Bio-Techne (NASDAQ:TECH)

Bio-Techne (NASDAQ:TECH) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/1/2018Deutsche BankSet Price TargetBuy -> Buy$154.00 -> $163.00LowView Rating Details
2/7/2018Craig HallumReiterated RatingBuy$140.00 -> $160.00MediumView Rating Details
2/7/2018Robert W. BairdBoost Price TargetOutperform -> Outperform$154.00 -> $157.00MediumView Rating Details
12/5/2017Leerink SwannReiterated RatingBuyMediumView Rating Details
10/24/2017CitigroupReiterated RatingBuy$125.00 -> $115.00N/AView Rating Details
7/13/2017Wells FargoInitiated CoverageMarket Perform -> Market PerformLowView Rating Details
3/27/2017Janney Montgomery ScottDowngradeBuy -> NeutralHighView Rating Details
(Data available from 4/19/2016 forward)

Earnings

Bio-Techne (NASDAQ:TECH) Earnings History and Estimates Chart

Earnings by Quarter for Bio-Techne (NASDAQ:TECH)

Bio-Techne (NASDAQ:TECH) Earnings Estimates

2018 EPS Consensus Estimate: $3.92
2019 EPS Consensus Estimate: $4.37
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181$0.88$0.88$0.88
Q2 20182$0.84$0.88$0.86
Q3 20182$0.96$1.09$1.03
Q4 20182$1.09$1.21$1.15
Q1 20192$0.89$1.02$0.96
Q2 20192$0.92$1.11$1.02
Q3 20192$1.04$1.24$1.14
Q4 20192$1.18$1.33$1.26

Bio-Techne (NASDAQ TECH) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/2/2018$1.12N/AView Earnings Details
2/6/2018Q2 2018$0.92$1.02$145.93 million$154.15 millionViewListenView Earnings Details
10/31/2017Q1 2018$0.82$0.90$142.37 million$144.61 millionViewN/AView Earnings Details
8/8/2017Q4 2017$0.99$1.09$150.25 million$156.60 millionViewListenView Earnings Details
5/2/2017Q3 2017$0.93$0.97$142.83 million$144.04 millionViewListenView Earnings Details
2/7/2017Q217$0.85$0.81$134.74 million$131.80 millionViewListenView Earnings Details
10/31/2016Q117$0.79$0.84$127.47 million$130.60 millionViewListenView Earnings Details
8/17/2016Q416$0.96$0.92$129.23 million$134.80 millionViewListenView Earnings Details
5/3/2016Q316$0.89$1.01$122.65 million$131.00 millionViewN/AView Earnings Details
2/2/2016Q216$0.82$0.88$118.59 million$120.90 millionViewN/AView Earnings Details
10/28/2015Q1$0.85$0.79$116.91 million$12.40 millionViewListenView Earnings Details
8/6/2015Q415$0.86$0.87$116.85 million$117.70 millionViewN/AView Earnings Details
5/5/2015Q315$0.91$0.86$119.30 million$114.20 millionViewN/AView Earnings Details
2/3/2015Q215$0.86$0.89$112.73 million$111.90 millionViewN/AView Earnings Details
10/28/2014Q115$0.87$0.85$108.65 million$108.50 millionViewN/AView Earnings Details
8/11/2014Q414$0.85$0.88$91.80 million$92.50 millionViewN/AView Earnings Details
4/28/2014Q314$0.89$0.94$92.50 million$95.60 millionViewN/AView Earnings Details
2/4/2014Q214$0.80$0.75$84.79 million$84.00 millionViewN/AView Earnings Details
10/29/2013Q114$0.80$0.83$82.36 million$85.70 millionViewN/AView Earnings Details
8/6/2013Q4 2013$0.83$0.82$79.71 million$79.50 millionViewN/AView Earnings Details
4/30/2013Q3 2013$0.90$0.88$84.00 million$81.00 millionViewN/AView Earnings Details
2/5/2013Q2 2013$0.77$0.74$76.40 million$75.10 millionViewN/AView Earnings Details
10/23/2012$0.79$0.75ViewN/AView Earnings Details
7/31/2012$0.85$0.80ViewN/AView Earnings Details
5/1/2012$0.89$0.90ViewN/AView Earnings Details
1/31/2012$0.79$0.76ViewN/AView Earnings Details
10/25/2011$0.84$0.81ViewN/AView Earnings Details
8/2/2011$0.76$0.76ViewN/AView Earnings Details
5/3/2011$0.80$0.84ViewN/AView Earnings Details
2/1/2011$0.68$0.71ViewN/AView Earnings Details
10/26/2010Q1 2011$0.73$0.71ViewN/AView Earnings Details
8/3/2010Q4 2010$0.71$0.69ViewN/AView Earnings Details
5/4/2010Q3 2010$0.79$0.87ViewN/AView Earnings Details
2/2/2010Q2 2010$0.68$0.66ViewN/AView Earnings Details
10/28/2009Q1 2010$0.70$0.72ViewN/AView Earnings Details
8/4/2009Q4 2009$0.69$0.68ViewN/AView Earnings Details
4/28/2009Q3 2009$0.72$0.74ViewN/AView Earnings Details
2/3/2009Q2 2009$0.64$0.62ViewN/AView Earnings Details
10/22/2008Q1 2009$0.66$0.74ViewN/AView Earnings Details
8/5/2008Q4 2008$0.67$0.70ViewN/AView Earnings Details
4/29/2008Q3 2008$0.66$0.76ViewN/AView Earnings Details
1/29/2008Q2 2008$0.54$0.60ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Bio-Techne (NASDAQ:TECH) Dividend Information

Bio-Techne pays an annual dividend of $1.28 per share, with a dividend yield of 0.84%. TECH's most recent quarterly dividend payment was Friday, March 2. Bio-Techne pays out 37.43% of its earnings out as a dividend.
Most Recent Dividend:3/2/2018
Annual Dividend:$1.28
Dividend Yield:0.84%
Payout Ratio:37.43% (Trailing 12 Months of Earnings)
31.92% (Based on This Year's Estimates)
27.83% (Based on Next Year's Estimates)
Dividend Payments by Quarter for Bio-Techne (NASDAQ:TECH)

Bio-Techne (NASDAQ:TECH) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
2/7/2018quarterly$0.320.94%2/15/20182/16/20183/2/2018
10/31/2017Quarterly$0.321%11/9/201711/10/201711/24/2017
8/9/2017Quarterly$0.321.1%8/16/20178/18/20179/1/2017
5/2/2017quarterly$0.321.15%5/17/20175/19/20176/2/2017
2/7/2017quarterly$0.321.27%2/15/20172/17/20173/3/2017
11/1/2016Quarterly$0.3211/9/201611/14/201611/28/2016
8/17/2016quarterly$0.328/25/20168/29/20169/12/2016
5/3/2016quarterly$0.321.27%5/11/20165/13/20165/27/2016
2/2/2016quarterly$0.321.48%2/10/20162/12/20162/26/2016
10/29/2015quarterly$0.321.45%11/10/201511/13/201511/27/2015
8/6/2015quarterly$0.321.18%8/13/20158/17/20158/28/2015
5/5/2015quarterly$0.321.31%5/11/20155/15/20155/29/2015
2/3/2015quarterly$0.321.4%2/11/20152/13/20152/27/2015
10/30/2014quarterly$0.321.41%11/6/201411/10/201411/24/2014
8/11/2014quarterly$0.311.31%8/19/20148/21/20148/29/2014
4/28/2014quarterly$0.311.37%5/7/20145/9/20145/23/2014
2/4/2014quarterly$0.311.48%2/12/20142/14/20142/28/2014
10/31/2013quarterly$0.311.4%11/7/201311/12/201311/25/2013
8/6/2013quarterly$0.301.62%8/14/20138/16/20138/31/2013
4/30/2013quarterly$0.301.86%5/8/20135/10/20135/24/2013
2/5/2013quarterly$0.301.74%2/13/20132/15/20133/1/2013
(Data available from 1/1/2013 forward)

Insider Trades

Bio-Techne (NASDAQ TECH) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 3.40%
Institutional Ownership Percentage: 97.14%
Insider Trading History for Bio-Techne (NASDAQ:TECH)
Institutional Ownership by Quarter for Bio-Techne (NASDAQ:TECH)

Bio-Techne (NASDAQ TECH) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/13/2018Charles A DinarelloDirectorSell5,000$136.06$680,300.00View SEC Filing  
11/1/2017Robert V BaumgartnerDirectorSell5,000$130.18$650,900.0012,712View SEC Filing  
10/10/2017Roger C LucasDirectorSell100$121.96$12,196.00View SEC Filing  
9/8/2017Roger C LucasDirectorSell100$120.94$12,094.001,970View SEC Filing  
9/6/2017Karen A HolbrookDirectorSell1,059$121.73$128,912.07914View SEC Filing  
8/10/2017Roger C LucasDirectorSell100$114.30$11,430.002,070View SEC Filing  
7/10/2017Roger C LucasDirectorSell100$116.86$11,686.002,170View SEC Filing  
6/9/2017Roger C LucasDirectorSell100$113.62$11,362.002,270View SEC Filing  
5/31/2017Charles A DinarelloDirectorSell5,000$111.37$556,850.0012,473View SEC Filing  
5/25/2017Karen A HolbrookDirectorSell5,000$111.15$555,750.006,973View SEC Filing  
5/10/2017Roger C LucasDirectorSell100$110.59$11,059.003,429View SEC Filing  
4/10/2017Roger C LucasDirectorSell100$101.15$10,115.003,529View SEC Filing  
1/10/2017Roger C LucasDirectorSell100$103.57$10,357.003,829View SEC Filing  
11/29/2016Karen A HolbrookDirectorSell1,000$106.73$106,730.001,973View SEC Filing  
11/16/2016Roger C LucasDirectorSell100$105.75$10,575.004,029View SEC Filing  
9/21/2016Roger C LucasDirectorSell100$108.91$10,891.003,315View SEC Filing  
9/8/2016John L HigginsDirectorSell1,700$109.83$186,711.001,359View SEC Filing  
9/8/2016Kevin S. GouldSVPSell524$110.50$57,902.00View SEC Filing  
9/2/2016Robert V BaumgartnerDirectorSell6,467$107.17$693,068.398,446View SEC Filing  
8/24/2016Robert V BaumgartnerDirectorSell3,533$107.10$378,384.309,592View SEC Filing  
8/17/2016Roger C. LucasDirectorSell100$113.70$11,370.00View SEC Filing  
7/20/2016Roger C LucasDirectorSell100$111.03$11,103.003,615View SEC Filing  
6/15/2016Roger C LucasDirectorSell100$112.15$11,215.003,715View SEC Filing  
5/18/2016Roger C LucasDirectorSell100$102.53$10,253.003,815View SEC Filing  
5/9/2016Charles A DinarelloDirectorSell5,000$101.91$509,550.006,559View SEC Filing  
5/6/2016Roger C LucasDirectorSell500$100.24$50,120.003,915View SEC Filing  
4/20/2016Roger C LucasDirectorSell100$92.40$9,240.004,315View SEC Filing  
3/16/2016Roger C LucasDirectorSell100$92.90$9,290.004,415View SEC Filing  
2/5/2016Roger C. LucasDirectorSell5,000$83.68$418,400.004,515View SEC Filing  
8/13/2015Roger C LucasDirectorSell5,000$106.01$530,050.00View SEC Filing  
6/8/2015Randolph C SteerDirectorSell1,000$99.39$99,390.00View SEC Filing  
2/19/2015Howard V OconnellDirectorSell5,000$95.78$478,900.00View SEC Filing  
12/10/2014Karen A HolbrookDirectorSell1,000$92.40$92,400.00View SEC Filing  
12/9/2014Kevin J ReaganVPSell3,591$89.35$320,855.85View SEC Filing  
12/8/2014Charles A DinarelloDirectorSell3,000$90.44$271,320.00View SEC Filing  
8/14/2014Karen A HolbrookDirectorSell5,000$95.54$477,700.00View SEC Filing  
5/7/2014Howard OconnellDirectorSell5,000$91.00$455,000.001,000View SEC Filing  
3/4/2014Karen HolbrookDirectorSell5,000$89.83$449,150.001,000View SEC Filing  
2/27/2014Randolph SteerDirectorSell5,000$88.78$443,900.001,000View SEC Filing  
11/13/2013Randolph SteerDirectorSell15,000$86.20$1,293,000.001,000View SEC Filing  
11/8/2013Robert BaumgartnerDirectorSell10,000$87.00$870,000.004,000View SEC Filing  
11/4/2013Roger C LucasDirectorSell10,000$87.64$876,400.00View SEC Filing  
5/6/2013Howard V OconnellDirectorBuy2,361$65.00$153,465.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Bio-Techne (NASDAQ TECH) News Headlines

Source:
DateHeadline
Bio-Techne (TECH) Coverage Initiated at Wells FargoBio-Techne (TECH) Coverage Initiated at Wells Fargo
www.americanbankingnews.com - April 18 at 1:56 PM
Analyzing Bio-Techne (TECH) & Osiris Therapeutics (OSIR)Analyzing Bio-Techne (TECH) & Osiris Therapeutics (OSIR)
www.americanbankingnews.com - April 16 at 7:07 PM
$164.72 Million in Sales Expected for Bio-Techne (TECH) This Quarter$164.72 Million in Sales Expected for Bio-Techne (TECH) This Quarter
www.americanbankingnews.com - April 14 at 3:51 AM
 Analysts Anticipate Bio-Techne (TECH) Will Announce Earnings of $1.14 Per Share Analysts Anticipate Bio-Techne (TECH) Will Announce Earnings of $1.14 Per Share
www.americanbankingnews.com - April 12 at 11:21 AM
BIO-TECHNE (TECH) Downgraded by Zacks Investment Research to "Hold"BIO-TECHNE (TECH) Downgraded by Zacks Investment Research to "Hold"
www.americanbankingnews.com - April 5 at 10:14 PM
BIO-TECHNE (TECH) Given Buy Rating at CitigroupBIO-TECHNE (TECH) Given Buy Rating at Citigroup
www.americanbankingnews.com - April 5 at 10:14 PM
BIO-TECHNE Corp (TECH) Given Average Rating of "Buy" by AnalystsBIO-TECHNE Corp (TECH) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - April 4 at 10:05 AM
BIO-TECHNE (TECH) Upgraded to Buy at ValuEngineBIO-TECHNE (TECH) Upgraded to Buy at ValuEngine
www.americanbankingnews.com - April 2 at 11:26 PM
BIO-TECHNE (TECH) Upgraded to "Buy" at BidaskClubBIO-TECHNE (TECH) Upgraded to "Buy" at BidaskClub
www.americanbankingnews.com - March 29 at 3:01 PM
 Analysts Anticipate BIO-TECHNE Corp (TECH) Will Post Quarterly Sales of $164.10 Million Analysts Anticipate BIO-TECHNE Corp (TECH) Will Post Quarterly Sales of $164.10 Million
www.americanbankingnews.com - March 28 at 8:09 AM
 Brokerages Anticipate BIO-TECHNE Corp (TECH) to Announce $1.15 EPS Brokerages Anticipate BIO-TECHNE Corp (TECH) to Announce $1.15 EPS
www.americanbankingnews.com - March 26 at 11:14 AM
3 Reasons Momentum Stock Investors Will Love Bio-Techne (TECH)3 Reasons Momentum Stock Investors Will Love Bio-Techne (TECH)
www.zacks.com - March 22 at 9:25 AM
Bio-Techne Expands RNAscope® ISH Automation - Facilitating Drug Discovery and DevelopmentBio-Techne Expands RNAscope® ISH Automation - Facilitating Drug Discovery and Development
www.prnewswire.com - March 21 at 1:24 PM
BidaskClub Upgrades BIO-TECHNE (TECH) to "Strong-Buy"BidaskClub Upgrades BIO-TECHNE (TECH) to "Strong-Buy"
www.americanbankingnews.com - March 16 at 10:28 PM
10 Growth Stocks for Long-Term Investors10 Growth Stocks for Long-Term Investors
finance.yahoo.com - March 15 at 9:04 AM
Bio-Techne Launches MimEX™ GI, an Accessible 3-D Cell Culturing Platform for the Gastrointestinal TractBio-Techne Launches MimEX™ GI, an Accessible 3-D Cell Culturing Platform for the Gastrointestinal Tract
finance.yahoo.com - March 14 at 6:02 PM
BIO-TECHNE Corp (TECH) Receives Average Rating of "Buy" from AnalystsBIO-TECHNE Corp (TECH) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - March 10 at 7:36 AM
BIO-TECHNE Corp (TECH) Expected to Post Earnings of $1.15 Per ShareBIO-TECHNE Corp (TECH) Expected to Post Earnings of $1.15 Per Share
www.americanbankingnews.com - March 9 at 5:58 AM
BIO-TECHNE Corp (TECH) Stake Decreased by Bank of New York Mellon CorpBIO-TECHNE Corp (TECH) Stake Decreased by Bank of New York Mellon Corp
www.americanbankingnews.com - March 6 at 4:54 AM
BIO-TECHNE Corp (TECH) Shares Bought by Arizona State Retirement SystemBIO-TECHNE Corp (TECH) Shares Bought by Arizona State Retirement System
www.americanbankingnews.com - March 3 at 4:22 AM
The Manufacturers Life Insurance Company  Grows Position in BIO-TECHNE Corp (TECH)The Manufacturers Life Insurance Company Grows Position in BIO-TECHNE Corp (TECH)
www.americanbankingnews.com - March 2 at 7:38 PM
BIO-TECHNE Corp (TECH) Position Raised by Snyder Capital Management L PBIO-TECHNE Corp (TECH) Position Raised by Snyder Capital Management L P
www.americanbankingnews.com - March 2 at 1:56 PM
Mackenzie Financial Corp Sells 143,295 Shares of BIO-TECHNE Corp (TECH)Mackenzie Financial Corp Sells 143,295 Shares of BIO-TECHNE Corp (TECH)
www.americanbankingnews.com - March 2 at 1:37 PM
BIO-TECHNE Corp (TECH) Shares Bought by California Public Employees Retirement SystemBIO-TECHNE Corp (TECH) Shares Bought by California Public Employees Retirement System
www.americanbankingnews.com - March 2 at 5:21 AM
BIO-TECHNE (TECH) PT Set at $163.00 by Deutsche BankBIO-TECHNE (TECH) PT Set at $163.00 by Deutsche Bank
www.americanbankingnews.com - March 1 at 7:15 PM
BIO-TECHNE Corp (TECH) Shares Sold by Rhumbline AdvisersBIO-TECHNE Corp (TECH) Shares Sold by Rhumbline Advisers
www.americanbankingnews.com - March 1 at 7:46 AM
BIO-TECHNE Corp (TECH) Stake Lifted by Jackson Square Partners LLCBIO-TECHNE Corp (TECH) Stake Lifted by Jackson Square Partners LLC
www.americanbankingnews.com - February 28 at 3:54 PM
BIO-TECHNE Corp (TECH) Shares Bought by Hudson Bay Capital Management LPBIO-TECHNE Corp (TECH) Shares Bought by Hudson Bay Capital Management LP
www.americanbankingnews.com - February 27 at 2:58 PM
BIO-TECHNE Corp (TECH) Holdings Reduced by FDx Advisors Inc.BIO-TECHNE Corp (TECH) Holdings Reduced by FDx Advisors Inc.
www.americanbankingnews.com - February 27 at 12:17 PM
BIO-TECHNE Corp (TECH) Shares Bought by American International Group Inc.BIO-TECHNE Corp (TECH) Shares Bought by American International Group Inc.
www.americanbankingnews.com - February 27 at 4:06 AM
Teacher Retirement System of Texas Has $1.65 Million Stake in BIO-TECHNE Corp (TECH)Teacher Retirement System of Texas Has $1.65 Million Stake in BIO-TECHNE Corp (TECH)
www.americanbankingnews.com - February 26 at 7:20 AM
Swiss National Bank Acquires 1,200 Shares of BIO-TECHNE Corp (TECH)Swiss National Bank Acquires 1,200 Shares of BIO-TECHNE Corp (TECH)
www.americanbankingnews.com - February 24 at 5:22 AM
$163.18 Million in Sales Expected for BIO-TECHNE Corp (TECH) This Quarter$163.18 Million in Sales Expected for BIO-TECHNE Corp (TECH) This Quarter
www.americanbankingnews.com - February 22 at 5:46 AM
BIO-TECHNE Corp (TECH) Expected to Announce Earnings of $1.14 Per ShareBIO-TECHNE Corp (TECH) Expected to Announce Earnings of $1.14 Per Share
www.americanbankingnews.com - February 20 at 4:08 PM
Bio-Techne Corporation (TECH) Presents At Leerink Partners 7th Annual Global Healthcare Conference - SlideshowBio-Techne Corporation (TECH) Presents At Leerink Partners 7th Annual Global Healthcare Conference - Slideshow
seekingalpha.com - February 17 at 8:48 AM
BIO-TECHNE Corp (TECH) Director Sells $680,300.00 in StockBIO-TECHNE Corp (TECH) Director Sells $680,300.00 in Stock
www.americanbankingnews.com - February 15 at 9:28 PM
Blog Exposure - AVEO Announced Positive NICE Recommendation for FOTIVDA(R) as First Line Treatment for Advanced Renal Cell CarcinomaBlog Exposure - AVEO Announced Positive NICE Recommendation for FOTIVDA(R) as First Line Treatment for Advanced Renal Cell Carcinoma
finance.yahoo.com - February 14 at 9:19 AM
BIO-TECHNE Corp (TECH) Given Average Recommendation of "Buy" by BrokeragesBIO-TECHNE Corp (TECH) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - February 13 at 11:04 AM
BIO-TECHNE (TECH) Lifted to Buy at Zacks Investment ResearchBIO-TECHNE (TECH) Lifted to Buy at Zacks Investment Research
www.americanbankingnews.com - February 10 at 1:30 PM
BIO-TECHNE Corp (TECH) to Post FY2018 Earnings of $4.07 Per Share, Leerink Swann ForecastsBIO-TECHNE Corp (TECH) to Post FY2018 Earnings of $4.07 Per Share, Leerink Swann Forecasts
www.americanbankingnews.com - February 9 at 12:28 PM
Q3 2018 Earnings Forecast for BIO-TECHNE Corp (TECH) Issued By Leerink SwannQ3 2018 Earnings Forecast for BIO-TECHNE Corp (TECH) Issued By Leerink Swann
www.americanbankingnews.com - February 8 at 11:37 AM
BIO-TECHNE Corp (TECH) Announces $0.32 Quarterly DividendBIO-TECHNE Corp (TECH) Announces $0.32 Quarterly Dividend
www.americanbankingnews.com - February 8 at 12:12 AM
BIO-TECHNEs (TECH) "Buy" Rating Reaffirmed at Craig HallumBIO-TECHNE's (TECH) "Buy" Rating Reaffirmed at Craig Hallum
www.americanbankingnews.com - February 7 at 1:24 PM
Bio-Techne Named "Researchers Choice" by CiteAbBio-Techne Named "Researchers' Choice" by CiteAb
finance.yahoo.com - February 7 at 9:23 AM
BIO-TECHNEs (TECH) "Buy" Rating Reiterated at Robert W. BairdBIO-TECHNE's (TECH) "Buy" Rating Reiterated at Robert W. Baird
www.americanbankingnews.com - February 7 at 8:36 AM
What does Bio-Techne Corporation’s (NASDAQ:TECH) Balance Sheet Tell Us About Its Future?What does Bio-Techne Corporation’s (NASDAQ:TECH) Balance Sheet Tell Us About Its Future?
finance.yahoo.com - February 6 at 4:16 PM
BIO-TECHNE (TECH) Issues  Earnings Results, Beats Estimates By $0.17 EPSBIO-TECHNE (TECH) Issues Earnings Results, Beats Estimates By $0.17 EPS
www.americanbankingnews.com - February 6 at 10:02 AM
Bio-Techne Q2 Profit Beats Estimates; Organic Revenue Up 14% - Quick FactsBio-Techne Q2 Profit Beats Estimates; Organic Revenue Up 14% - Quick Facts
www.nasdaq.com - February 6 at 9:18 AM
BRIEF-Bio-Techne Q2 GAAP Earnings Per Share $1.29BRIEF-Bio-Techne Q2 GAAP Earnings Per Share $1.29
www.reuters.com - February 6 at 9:18 AM
Bio-Techne Releases Second Quarter Fiscal 2018 ResultsBio-Techne Releases Second Quarter Fiscal 2018 Results
finance.yahoo.com - February 6 at 9:18 AM

SEC Filings

Bio-Techne (NASDAQ:TECH) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Bio-Techne (NASDAQ:TECH) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Bio-Techne (NASDAQ TECH) Stock Chart for Thursday, April, 19, 2018

Loading chart…

This page was last updated on 4/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.